Œ»‚ „‰½ ¼½»‰½¹½...

download Œ»‚ „‰½ ¼½»‰½¹½ ±½„¹ƒ‰¼¬„‰½ ƒ„·½ ±½„¹¼µ„€¹ƒ·

of 22

  • date post

    06-Jan-2016
  • Category

    Documents

  • view

    215
  • download

    0

Embed Size (px)

description

Ελεύθερη ανακοίνωση στο 21ο ΕΣΦΙΕ, Αθήνα, 2015Συγγραφείς: Καράγιωργα Ιφιγένεια, Λαβασίδης Γιώργος

Transcript of Œ»‚ „‰½ ¼½»‰½¹½...

  • Crohn

    1

    1

    2

    1/- 4 2

  • Crohn

    ( )

    ,

    : 20-30 60-70

  • -

  • Bowel rest

  • Anti-TNF

    Infliximab

    Adalimumab

    Certolizumab pegol

    Anti-integrin 4 Vedolizumab

    Natalizumab

  • Infliximab

    EMA approval: 1999

    mAb IgG1 -

    :

    Crohn

  • :

    , ,

    :

    , , , , ,

  • Adalimumab

    EMA approval: 2003

    mAb IgG1

    TNF

    :

    Crohn

  • :

    infliximab

    :

    , , , -, , ,

  • Certolizumab pegol

    FDA approval: 2008

  • - (Kawalek et al, 2013)

  • The role of selected integrinsin lymphocyte migration

  • Natalizumab

    FDA approval: 2008

    -4

    PML (JC virus) EMA

    MS

  • Vedolizumab

    EMA approval: 2014

    mAb IgG1 -47

  • :

    Crohn, anti-TNF ( )

  • :

    ,

    :

    , ,

  • CD + UC = IBD

    anti-TNF anti-integrin 4 nti-TNF: infliximab, adalimumab

    Anti-integrin 4: vedolizumab